In Minnesota, angels smile on medical devices

Some 29 medical device makers benefited in 2011 by a Minnesota program that provides tax credits to angel investors, those affluent individuals who put up capital to nurture new businesses.

According to a March 20 report from the North Star State’s Department of Employment and Economic Development, the program helped a total of 113 startups and led to the creation of 102 new jobs. The medical device industry proved the top attractor of investors and, with $12.6 million, came in just behind biotechnology in total dollars drawn.

Among the manufacturers finding friends in incentivized angel investors were AUM Cardiovascular, Nascent Surgical and Pursuit Vascular. 

A handful of healthcare software developers, along with eight companies working in unspecified healthcare services, also received angel dollars through the program; in fact, of the five best-invested industries, only clean technology had no healthcare entrants.

Healthcare’s dominance of angel investments in Minnesota, and the medical device industry’s standing atop healthcare there, are consistent with national venture-capital trends.
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.